{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:38:32Z","timestamp":1782193112907,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Italian Association for Cancer Research (AIRC)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Discovery Today: Technologies"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ddtec.2014.03.001","type":"journal-article","created":{"date-parts":[[2014,3,23]],"date-time":"2014-03-23T09:10:18Z","timestamp":1395565818000},"page":"73-79","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Resistance to minor groove binders"],"prefix":"10.1016","volume":"11","author":[{"given":"Benedetta","family":"Colmegna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Uboldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Erba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"D\u2019Incalci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ddtec.2014.03.001_bib0005","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1021\/jm00124a008","article-title":"Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives","volume":"32","author":"Arcamone","year":"1989","journal-title":"J Med Chem"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0010","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/bjc.1993.454","article-title":"Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517)","volume":"68","author":"Capolongo","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0015","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ijc.2910530223","article-title":"Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies","volume":"53","author":"Geroni","year":"1993","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0020","first-page":"2821","article-title":"Mechanism of interaction of CC-1065 (NSC 298223) with DNA","volume":"42","author":"Swenson","year":"1982","journal-title":"Cancer Res"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7164\/antibiotics.39.319","article-title":"The chemistry, mechanism of action and biological properties of CC-1065, a potent antitumor antibiotic","volume":"39","author":"Reynolds","year":"1986","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0030","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/carcin\/11.4.659","article-title":"Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: ligand-induced DNA\u2013protein crosslinking and responses to topoisomerase poisons","volume":"11","author":"Smith","year":"1990","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0035","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/sj.bjc.6690360","article-title":"Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents","volume":"80","author":"Colella","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0040","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/sj.bjc.6601316","article-title":"Brostallicin (PNU-166196) \u2013 a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells","volume":"89","author":"Fedier","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0045","first-page":"712","article-title":"A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors","volume":"8","author":"Pitot","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0050","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdg215","article-title":"A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies","volume":"14","author":"Schwartz","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00944178","article-title":"Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells","volume":"10","author":"Volpe","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0060","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/bjc.1997.155","article-title":"Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells","volume":"75","author":"Ghielmini","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0065","first-page":"1732","article-title":"Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743)","volume":"82","author":"Erba","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10637-006-7773-9","article-title":"Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype","volume":"25","author":"Beumer","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0075","first-page":"3893","article-title":"Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells","volume":"8","author":"Scotlandi","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0080","first-page":"1605","article-title":"The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71","volume":"27","author":"Manara","year":"2005","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0085","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1073\/pnas.97.12.6780","article-title":"Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743","volume":"97","author":"Minuzzo","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0090","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1124\/mol.105.013615","article-title":"Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters","volume":"68","author":"Minuzzo","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0095","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.1073\/pnas.97.12.6775","article-title":"Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation","volume":"97","author":"Jin","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0100","first-page":"1327","article-title":"Overcoming multidrug drug resistance in P-glycoprotein\/MDR1-overexpressing cell lines by ecteinascidin 743","volume":"1","author":"Kanzaki","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0105","doi-asserted-by":"crossref","first-page":"e6967","DOI":"10.1371\/journal.pone.0006967","article-title":"ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines","volume":"4","author":"Duan","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ejca.2004.10.021","article-title":"Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743","volume":"41","author":"Marchini","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0115","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.bcp.2003.08.033","article-title":"Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations","volume":"66","author":"Shao","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0120","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","article-title":"Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0125","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1021\/ja004023p","article-title":"Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites","volume":"123","author":"Zewail-Foote","year":"2001","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0130","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ijc.1221","article-title":"Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways","volume":"92","author":"Damia","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0959-8049(00)00357-9","article-title":"Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action","volume":"37","author":"Erba","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0140","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ejca.2008.01.003","article-title":"Role of homologous recombination in trabectedin-induced DNA damage","volume":"44","author":"Tavecchio","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0145","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2184.2007.00469.x","article-title":"Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach","volume":"40","author":"Tavecchio","year":"2007","journal-title":"Cell Prolif"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0150","doi-asserted-by":"crossref","first-page":"e1003293","DOI":"10.1371\/journal.pcbi.1003293","article-title":"Dynamic rendering of the heterogeneous cell response to anticancer treatments","volume":"9","author":"Falcetta","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0155","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1476-4598-9-259","article-title":"Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells","volume":"9","author":"Sabatino","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0160","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0165","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/annonc\/mdp004","article-title":"Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series","volume":"20","author":"Grosso","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0170","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/1535-7163.MCT-08-0848","article-title":"Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors","volume":"8","author":"Forni","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ddtec.2014.03.001_sbref0175","article-title":"Mode of action of trabectedin in myxoid liposarcomas","author":"Di Giandomenico","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ddtec.2014.03.001_sbref0180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ijc.26340","article-title":"Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents","volume":"131","author":"Uboldi","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_sbref0185","doi-asserted-by":"crossref","first-page":"e35423","DOI":"10.1371\/journal.pone.0035423","article-title":"A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma","volume":"7","author":"Uboldi","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ddtec.2014.03.001_sbref0190","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of macrophage targeting in the antitumor activity of trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0195","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ejca.2011.01.016","article-title":"Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study","volume":"47","author":"Sch\u00f6ffski","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ddtec.2014.03.001_bib0200","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/00001813-199908000-00006","article-title":"FCE 24517-resistant MCF-7 human breast cancer cell line: selection and characterization","volume":"10","author":"Salvatore","year":"1999","journal-title":"Anticancer Drugs"}],"container-title":["Drug Discovery Today: Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1740674914000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1740674914000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T14:53:08Z","timestamp":1538751188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1740674914000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":40,"alternative-id":["S1740674914000079"],"URL":"https:\/\/doi.org\/10.1016\/j.ddtec.2014.03.001","relation":{},"ISSN":["1740-6749"],"issn-type":[{"value":"1740-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}